Reckitt Benckiser
As of the edition of 20 October 2026, Reckitt Benckiser runs 15 drugs, 15 of them marketed; it is on route A at 0 targets and on route B at 3 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Reckitt Benckiser Healthcare (UK) Limited: acquired in 2017; successor RECKITT BENCKISER GROUP PLC
Drugs by status
| Status | Count |
|---|---|
| Marketed | 15 |
| Total | 15 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Acetaminophen | none listed | 17 |
| Ibuprofen | none listed | 11 |
| Buprenorphine | Ends 2028 (exclusivity) | 9 |
| Ascorbic acid | none listed | 0 |
| Phenylephrine | none listed | 6 |
| Dextromethorphan | none listed | 5 |
| Sodium bicarbonate | none listed | 0 |
| Calcium carbonate | none listed | 0 |
| Flurbiprofen | none listed | 4 |
| Menthol | none listed | 3 |
| Guaifenesin | none listed | 0 |
| Levomenthol | none listed | 2 |
| Amylmetacresol | none listed | 0 |
| Chloroxylenol | none listed | 0 |
| Hexylresorcinol | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 3 targets.
All 3 rows on route A or B
In the product3 company-target rows on route A or B; 0 are not shown here, and no score is.
See all 3 targets where Reckitt Benckiser needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.